Integrated DNA Technologies and Glycon Partner in Australia
News Apr 23, 2010
IDT is among the world’s most respected manufacturers of custom synthetic oligonucleotides and genes. Glycon will offer Australia’s scientists local sales and technical support of IDT’s products, complementing IDT’s existing global customer care network available by phone, email and web chat.
Glycon brings more than a decade’s experience in Australia’s biotechnology sector, with advanced expertise in both oligonucleotides and genetic research. Australian scientists will be able to work directly with Glycon to take the maximum advantage of IDT’s entire product portfolio of synthetic DNA and RNA oligos, genes, and supporting products.
Wendy Scott, Executive Sales Manager of Gylcon explains the benefits of this relationship, “Our experience and knowledge of IDT’s products enables us to provide exceptional customer service and technical expertise. With our background in biomedical science, broad product knowledge base and customer service experience, we can find the most effective solution for all research needs.”
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Genetic Discovery Helps Determine the Difference Between Aggressive & Benign Bone TumorsNews
The first genetic marker for the bone tumor, osteoblastoma, has been discovered. Whole-genome and transcriptome sequencing of human bone tumors revealed that a genetic change that affects the transcription factor, FOS, is a hallmark mutation of osteoblastoma. The results will help clinicians correctly distinguish benign osteoblastoma tumors from aggressive osteosarcoma tumors and direct the correct treatment.READ MORE
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018